UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

The New England journal of medicine, 2014-09, Vol.371 (11), p.1028-1038

2014

Link zum Volltext

Verfügbarkeit prüfen

Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Molecular imaging and biology, 2015-08, Vol.17 (4), p.565-574

2015

Link zum Volltext

Verfügbarkeit prüfen

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

European urology, 2018-09, Vol.74 (3), p.283-291

2018

Link zum Volltext

Verfügbarkeit prüfen

MSH2 Loss in Primary Prostate Cancer

Clinical cancer research, 2017-11, Vol.23 (22), p.6863-6874

2017

Link zum Volltext

Verfügbarkeit prüfen

Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer

European urology, 2012-01, Vol.61 (1), p.11-25

2012

Link zum Volltext

Verfügbarkeit prüfen

Expanding Treatment Options for Metastatic Prostate Cancer

The New England journal of medicine, 2011-05, Vol.364 (21), p.2055-2058

2011

Link zum Volltext

Verfügbarkeit prüfen

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

Nature medicine, 2009-05, Vol.15 (5), p.559-565

2009

Link zum Volltext

Verfügbarkeit prüfen

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1148-1159

2008

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

The New England journal of medicine, 2004-10, Vol.351 (15), p.1502-1512

2004

Link zum Volltext

Verfügbarkeit prüfen

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Clinical cancer research, 2016-03, Vol.22 (6), p.1356-1363

2016

Link zum Volltext

Verfügbarkeit prüfen

Advances in the Treatment of Metastatic Prostate Cancer

Mayo Clinic proceedings, 2015-12, Vol.90 (12), p.1719-1733

2015

Link zum Volltext

Verfügbarkeit prüfen

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

Journal of clinical oncology, 2012-02, Vol.30 (5), p.507-512

2012

Link zum Volltext

Verfügbarkeit prüfen

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Nature communications, 2024-01, Vol.15 (1), p.14-14, Article 14

2024

Link zum Volltext

Verfügbarkeit prüfen

Novel targeted therapeutics for metastatic castration-resistant prostate cancer

Cancer letters, 2010-05, Vol.291 (1), p.1-13

2010

Link zum Volltext

Verfügbarkeit prüfen

Genomic and clinical characterization of pulmonary‐only metastatic prostate cancer: A unique molecular subtype

The Prostate, 2019-09, Vol.79 (13), p.1572-1579

2019

Link zum Volltext

Verfügbarkeit prüfen

Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital

Urology (Ridgewood, N.J.), 2015-09, Vol.86 (3), p.539-543

2015

Link zum Volltext

Verfügbarkeit prüfen

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy

Urologic oncology, 2012-09, Vol.30 (5), p.607-613

2012

Link zum Volltext

Verfügbarkeit prüfen

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy

Clinical cancer research, 2005-06, Vol.11 (11), p.4037-4043

2005

Link zum Volltext

Verfügbarkeit prüfen

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2149-2156

2017

Link zum Volltext

Verfügbarkeit prüfen

Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy

Clinical cancer research, 2005-12, Vol.11 (23), p.8321-8325

2005

Link zum Volltext

Verfügbarkeit prüfen

Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer

Hematology/oncology clinics of North America, 2013-12, Vol.27 (6), p.1205-1219

2013

Link zum Volltext

Verfügbarkeit prüfen

There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive

Journal of clinical oncology, 2018-10, Vol.36 (30), p.3059-3060

2018

Link zum Volltext

Verfügbarkeit prüfen

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

European urology, 2019-10, Vol.76 (4), p.452-458

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 495

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(464)
Mit Volltextzugriff
(416)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(495)
Japanisch
(40)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(152)
The Journal Of Urology
(37)
The Prostate
(28)
European Urology
(23)
The New England Journal Of Medicine
(20)
Clinical Cancer Research
(18)
Urology
(18)
Cancer
(16)
Jnci : Journal Of The National Cancer Institute
(10)
Investigational New Drugs
(9)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

MSH2 Loss in Primary Prostate Cancer

Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer

Expanding Treatment Options for Metastatic Prostate Cancer

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Advances in the Treatment of Metastatic Prostate Cancer

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Novel targeted therapeutics for metastatic castration-resistant prostate cancer

Genomic and clinical characterization of pulmonary‐only metastatic prostate cancer: A unique molecular subtype

Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy

High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy

Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer

There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

Suchergebnisse filtern